Clinical Trials
69 trialsTRIDENT-1
Turning Point Therapeutics, Inc.
INDIGO
Boston Scientific Corporation
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
GRECCAR 5
University Hospital, Bordeaux
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Alterome Therapeutics, Inc.
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
ROWAN
Boston Scientific Corporation
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Pfizer
LIBRETTO-001
Eli Lilly and Company
DETERMINE
Cancer Research UK
LIBRETTO-121
Eli Lilly and Company
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
DETERMINE
Cancer Research UK
DETERMINE
Cancer Research UK
DETERMINE
Cancer Research UK
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
Elevation Oncology
START-001
Marengo Therapeutics, Inc.
ARROW
Hoffmann-La Roche
Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
Thomas Jefferson University
Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca
Thomas Jefferson University
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.
Boston Scientific Corporation
OPTIMA
Imunon
OSPREY
OncoSil Medical Limited
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Kyowa Kirin Co., Ltd.
Evaluate the Efficacy of Adding Intraluminal Brachytherapy After CCRT for Local-regional Thoracic Esophageal Cancer.
Taipei Veterans General Hospital, Taiwan
ASPIRIN
University Hospital, Antwerp
CanStem303C
Sumitomo Pharma America, Inc.
CanStem111P
Sumitomo Pharma America, Inc.
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
Sumitomo Pharma America, Inc.
Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study
The Second Affiliated Hospital of Fujian Medical University
ALpha-T
Hoffmann-La Roche
apact
Celgene
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Revolution Medicines, Inc.
SEPTRALU
Sociedad Española de Medicina Nuclear e Imagen Molecular
ALTER-E005
Jiangxi Provincial Cancer Hospital
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
ALTER-C-002
Zhejiang University
Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases
State Scientific Centre of Coloproctology, Russian Federation
STTELS
Seoul National University Bundang Hospital
SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib
Gachon University Gil Medical Center
CLEAR-C
Zhejiang University
An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer
Isofol Medical AB
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
MERCURY II
Royal Marsden NHS Foundation Trust
Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks
Royal Marsden NHS Foundation Trust
MARVEL
Royal Marsden NHS Foundation Trust